Abbott: brands it owns and its ownership tree
Abbott (NYSE: ABT) is a publicly listed company headquartered in Abbott Park, Illinois, United States that owns 6 consumer brands across 2 categories.[1][2]
Abbott is an Illinois corporation incorporated in 1900 and one of the largest diversified healthcare companies in the world. It reports in four segments — Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices — and only the third of those puts Abbott's names on supermarket shelves. Its 10-K lists Similac and EleCare in infant formula, Ensure, Glucerna, PediaSure and Pedialyte in adult and other paediatric nutrition, and a separate range of enteral feeds such as Jevity, Osmolite and Nepro sold into hospitals. The larger part of the company is diagnostics and devices, including the FreeStyle Libre glucose monitors, the BinaxNOW rapid tests and the i-STAT point-of-care systems, none of which is a consumer brand in the sense this site uses. Abbott agreed to acquire Exact Sciences in November 2025.
-
brands owned
-
2
categories
-
0
acquisitions recorded
-
0
divestitures recorded
Company facts
- Legal name
- Abbott Laboratories
- Type
- publicly listed company · see all publicly listed company owners
- Headquarters
- 🇺🇸 Abbott Park, Illinois, United States
- Founded
- 1900
- Tickers
- NYSE: ABT
- Revenue
- $44.3 billion (2025)[2]
- SEC CIK
- 0000001800
- Website
- www.abbott.com
- Last verified
- · 2 sources
What Abbott's annual report says about its business
Read from Abbott's latest annual filing[1]. Each line gives the sentence the filing uses, copied word for word.
Segments the filing names
- Established Pharmaceutical Products, Diagnostic Products:
Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
- Nutritional Products:
In Abbott's Nutritional Products segment, total pediatric nutrition sales, excluding the impact of foreign exchange, decreased 0.7 percent in 2025, reflecting lower sales volumes in the U.S., partially offset by higher international sales and price increases.
- Medical Devices:
With respect to the performance of each reportable segment over the last three years, sales in the Medical Devices segment, excluding the impact of foreign exchange, increased 11.9 percent in 2025 and 13.7 percent in 2024.
- Diagnostics:
In Abbott's Diagnostics segment, sales decreased 4.5 percent in 2025 and 3.9 percent in 2024, excluding the impact of foreign exchange.
- Established Pharmaceutical Products Segment:
The increase in total net sales in 2025, excluding the impact of foreign exchange, primarily reflects higher sales in the Medical Devices and Established Pharmaceutical Products segments.
- Nutritional Products segment:
Nutritional Products segment sales for the year remained relatively unchanged, reflecting price increases and lower volumes.
- Diagnostic Products segment:
Diagnostic Products segment sales continued to be impacted by the decline in COVID-19 testing-related sales and challenging market conditions in China.
Acquisitions and disposals named in the filing
- Acquired: Exact Sciences, $20 billion.
Abbott plans to fund the Exact Sciences acquisition with approximately $20 billion of borrowings.
- Acquired: Bigfoot (September 22, 2023).
On September 22, 2023, Abbott completed the acquisition of Bigfoot, which furthers Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.
- Acquired: Cardiovascular Systems, Inc. (CSI) (April 27, 2023), $851 million.
On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of $851 million .
- Sold or exited: ZonePerfect product line (March 2024).
In 2025, U.S. Adult Nutritionals sales decreased 2.2 percent, reflecting lower Ensure product sales and the discontinuation of the ZonePerfect product line in March 2024, partially offset by growth in Glucerna product sales.
Abbott in numbers
- Abbott owns 6 consumer brands tracked here across 2 top-level categories; the largest is food with 5 brands.[1]
Abbott financial history
Headline figures from Abbott's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2020–2025. Revenue moved from $34.6bn to $44.3bn, an average of 5.1% a year (calculated).
| Fiscal year ended | Revenue | Operating income | Operating margin | Net income | Total assets | Long-term debt | Filing |
|---|---|---|---|---|---|---|---|
| $44.3bn | $8.05bn | 18.2% | $6.52bn | $86.7bn | $9.9bn | 10-K | |
| $42bn | $6.83bn | 16.3% | $13.4bn | $81.4bn | $12.6bn | 10-K | |
| $40.1bn | $6.48bn | 16.2% | $5.72bn | $73.2bn | $13.6bn | 10-K | |
| $43.7bn | $8.36bn | 19.2% | $6.93bn | $74.4bn | $14.5bn | 10-K | |
| $43.1bn | $8.43bn | 19.6% | $7.07bn | $75.2bn | $17.3bn | 10-K | |
| $34.6bn | $5.36bn | 15.5% | $4.5bn | $72.5bn | $18.5bn | 10-K |
Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.
Everything Abbott owns
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Full-screen interactive tree → · Download as infographic
Brand portfolio by category
Recent changes to this record
Abbott SEC filings
The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.
Annual reports
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
Proxy statements
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
Recent current and quarterly reports
| Filed | Form | What it declares |
|---|---|---|
| 8-K | Regulation FD disclosure; Other events | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 10-Q | Quarterly report | |
| 8-K | Departure or appointment of directors or officers; Change to articles or bylaws; Results of a shareholder vote | |
| 8-K | Other events | |
| 8-K | Results of operations and financial condition | |
| 8-K | Other events | |
| 8-K | Entry into a material agreement; Creation of a direct financial obligation | |
| 8-K | Entry into a material agreement | |
| 8-K | Change to articles or bylaws | |
| 8-K | Results of operations and financial condition | |
| 8-K | Departure or appointment of directors or officers; Change to articles or bylaws | |
| 8-K | Trading suspension in employee plans |
Official recalls involving Abbott products
2 recall notices from government regulators matched to Abbott. Each applies to the specific products, sizes and lot codes named in the notice, not to every product sold under the name.
- Ensure NutriVigor Plant-Based Almond flavour Nutritional Shake — UK FSA, · Allergy alert
Reason given: Milk
Recalling firm: Abbott · Brand: Ensure
- Similac Probiotic Tri-Blend - 0.017oz (0.50g) packaged in foil packets. 50 foil packets per carton - 3 cartons per case. — FDA, · Class II
Reason given: Marketed towards preterm infants without approval as a new drug or licensed biologic, as well as unsafe food additive
Recalling firm: Abbott Laboratories · Brand: Similac
Matched automatically from FDA, USDA FSIS, UK Food Standards Agency and CPSC records only when the recalling firm corresponds to this ownership record and, for a brand, the brand name appears in the product description. Check the linked notice for exact products and lots. Method.
Frequently asked questions
What brands does Abbott own?
Abbott owns 6 consumer brands tracked here, including Similac, Ensure, EleCare, PediaSure, Glucerna and Pedialyte.
Is Abbott an American company?
Yes. Abbott is headquartered in Abbott Park, Illinois, United States and was founded in 1900.
Who owns Abbott?
Abbott is a publicly listed company owned by its shareholders; it trades as ABT on the NYSE.
Sources (2) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Abbott Laboratories Annual Report on Form 10-K filed 2026-02-20 — SEC EDGAR, SEC Form 10-K, published 20 February 2026; retrieved 26 September 2026.
- [2] Abbott Laboratories: Form 10-K for the year ended 2025-12-31 (revenue) — SEC EDGAR, SEC Form 10-K, published 20 February 2026; retrieved 4 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.